期刊
FUTURE MEDICINAL CHEMISTRY
卷 8, 期 4, 页码 443-462出版社
FUTURE SCI LTD
DOI: 10.4155/fmc.16.6
关键词
AAs; angiogenesis; antiangiogenics; biomarkers; combination therapies; metastasis; metronomic chemotherapy; resistance; tumor vasculature-disrupting agents; tumor VDAs
Angiogenesis is a process essential for tumor growth and metastasis. Inhibition of angiogenesis as an anticancer strategy has shown only moderately improved results and is beset with practical limitations, despite theoretical therapeutic advantages. Inevitably resistance develops, through redundancy of signaling pathways and selection for subclonal populations adapted for hypoxic conditions, with more invasive phenotypes. Antiangiogenic-targeted therapies may find improved efficacy in combination therapies; with others in this class, that directly or indirectly target separate pathways or different components of the same pathway, or with a separate class of tumor vasculature-disrupting agents. This review discusses the challenges and strategies for optimization of combination therapies including metronomic administration of drugs and the need for suitable prognostic and surrogate response biomarkers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据